The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Ebola Virus‐Like Particle–Based Vaccine Protects Nonhuman Primates against Lethal Ebola Virus Challenge
Open accessAbstract
BACKGROUND: Currently, there are no licensed vaccines or therapeutics for the prevention or treatment of infection by the highly lethal filoviruses, Ebola virus (EBOV) and Marburg virus (MARV), in humans. We previously had demonstrated the protective efficacy of virus-like particle (VLP)-based vaccines against EBOV and MARV infection in rodents. METHODS: To determine the efficacy of vaccination with Ebola VLPs (eVLPs) in nonhuman primates, we vaccinated cynomolgus macaques with eVLPs containing EBOV glycoprotein (GP), nucleoprotein (NP), and VP40 matrix protein and challenged the macaques with 1000 pfu of EBOV. RESULTS: Serum samples from the eVLP-vaccinated nonhuman primates demonstrated EBOV-specific antibody titers, as measured by enzyme-linked immunosorbent assay, complement-mediated lysis assay, and antibody-dependent cell-mediated cytotoxicity assay. CD44+ T cells from eVLP-vaccinated macaques but not from a naive macaque responded with vigorous production of tumor necrosis factor- alpha after EBOV-peptide stimulation. All 5 eVLP-vaccinated monkeys survived challenge without clinical or laboratory signs of EBOV infection, whereas the control animal died of infection. CONCLUSION: On the basis of safety and efficacy, eVLPs represent a promising filovirus vaccine for use in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
The 1996 Guide for the Care and Use of Laboratory Animals
Clark, J. D., Gebhart, G. F., Gonder, J. C., Keeling, M. E., & Kohn, D. F. (1997) · ILAR Journal · doi:10.1093/ilar.38.1.41 · Cited by 4,417
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
Jones, S. M., Feldmann, H., Ströher, U., Geisbert, J. B., Fernando, L., Grolla, A., Klenk, H.-D., Sullivan, N. J., Volchkov, V. E., Fritz, E. A., et al. (2005) · Nature Medicine · doi:10.1038/nm1258 · Cited by 687
Virus-like particles as immunogens
Noad, R., & Roy, P. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(03)00208-7 · Cited by 581
Epitopes Involved in Antibody-Mediated Protection from Ebola Virus
Wilson, J. A., Hevey, M., Bakken, R., Guest, S., Bray, M., Schmaljohn, A. L., & Hart, M. K. (2000) · Science · doi:10.1126/science.287.5458.1664 · Cited by 459
Bavari, S., Bosio, C. M., Wiegand, E., Ruthel, G., Will, A. B., Geisbert, T. W., Hevey, M., Schmaljohn, C., Schmaljohn, A., & Aman, M. J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011500 · Cited by 432
Self-citationGeisbert, T. W., Hensley, L. E., Jahrling, P. B., Larsen, T., Geisbert, J. B., Paragas, J., Young, H. A., Fredeking, T. M., Rote, W. E., & Vlasuk, G. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15012-x · Cited by 382
Ebola Virus VP40 Drives the Formation of Virus-Like Filamentous Particles Along with GP
Noda, T., Sagara, H., Suzuki, E., Takada, A., Kida, H., & Kawaoka, Y. (2002) · Journal of Virology · doi:10.1128/jvi.76.10.4855-4865.2002 · Cited by 349
Jahrling, P. B., Geisbert, T. W., Geisbert, J. B., Swearengen, J. R., Bray, M., Jaax, N. K., Huggins, J. W., LeDuc, J. W., & Peters, C. J. (1999) · The Journal of Infectious Diseases · doi:10.1086/514310 · Cited by 269
Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates
Hevey, M., Negley, D., Pushko, P., Smith, J., & Schmaljohn, A. (1998) · Virology · doi:10.1006/viro.1998.9367 · Cited by 262
Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
Geisbert, T. W., Pushko, P., Anderson, K., Smith, J., Davis, K. J., & Jahrling, P. B. (2002) · Emerging Infectious Diseases · doi:10.3201/eid0805.010284 · Cited by 248
Ebola virus-like particles protect from lethal Ebola virus infection
Warfield, K. L., Bosio, C. M., Welcher, B. C., Deal, E. M., Mohamadzadeh, M., Schmaljohn, A., Aman, M. J., & Bavari, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2237038100 · Cited by 244
Self-citationLicata, J. M., Johnson, R. F., Han, Z., & Harty, R. N. (2004) · Journal of Virology · doi:10.1128/jvi.78.14.7344-7351.2004 · Cited by 236
Neutralizing Antibody Fails to Impact the Course of Ebola Virus Infection in Monkeys
Oswald, W. B., Geisbert, T. W., Davis, K. J., Geisbert, J. B., Sullivan, N. J., Jahrling, P. B., Parren, P. W. H. I., & Burton, D. R. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030009 · Cited by 230
Sullivan, N. J., Geisbert, T. W., Geisbert, J. B., Shedlock, D. J., Xu, L., Lamoreaux, L., Custers, J. H. H. V., Popernack, P. M., Yang, Z.-Y., Pau, M. G., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030177 · Cited by 205
Pushko, P., Bray, M., Ludwig, G. V., Parker, M., Schmaljohn, A., Sanchez, A., Jahrling, P. B., & Smith, J. F. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00113-4 · Cited by 198
Nedd4 Regulates Egress of Ebola Virus-Like Particles from Host Cells
Yasuda, J., Nakao, M., Kawaoka, Y., & Shida, H. (2003) · Journal of Virology · doi:10.1128/jvi.77.18.9987-9992.2003 · Cited by 184
DNA Vaccines Expressing either the GP or NP Genes of Ebola Virus Protect Mice from Lethal Challenge
Vanderzanden, L., Bray, M., Fuller, D., Roberts, T., Custer, D., Spik, K., Jahrling, P., Huggins, J., Schmaljohn, A., & Schmaljohn, C. (1998) · Virology · doi:10.1006/viro.1998.9176 · Cited by 172
Role of Natural Killer Cells in Innate Protection against Lethal Ebola Virus Infection
Warfield, K. L., Perkins, J. G., Swenson, D. L., Deal, E. M., Bosio, C. M., Aman, M. J., Yokoyama, W. M., Young, H. A., & Bavari, S. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20032141 · Cited by 148
Self-citationWhite, A. R. (2006) · Acupuncture in Medicine · doi:10.1136/aim.24.suppl.iii · Cited by 142
Han, Z., Boshra, H., Sunyer, J. O., Zwiers, S. H., Paragas, J., & Harty, R. N. (2003) · Journal of Virology · doi:10.1128/jvi.77.3.1793-1800.2003 · Cited by 134
Dowling, W. E., Thompson, E. A., Badger, C. V., Mellquist, J. L., Garrison, A. R., Smith, J. M., Paragas, J., Hogan, R. J., & Schmaljohn, C. S. (2006) · Journal of Virology · doi:10.1128/jvi.02098-06 · Cited by 134
Swenson, D. L., Warfield, K. L., Negley, D. L., Schmaljohn, A. L., Aman, M. J., & Bavari, S. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.11.070 · Cited by 133
Self-citationMellquist-Riemenschneider, J. L., Garrison, A. R., Geisbert, J. B., Jahrling, P. B., Hevey, M., Negley, D. L., Schmaljohn, A. L., Lee, J., Hart, M. K., Vanderzanden, L., et al. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00362-1 · Cited by 133
Vaccine Potential of Ebola Virus VP24, VP30, VP35, and VP40 Proteins
Wilson, J. A., Bray, M., Bakken, R. R., & Hart, M. K. (2001) · Virology · doi:10.1006/viro.2001.1012 · Cited by 109
Ye, L., Lin, J., Sun, Y., Bennouna, S., Lo, M. K., Wu, Q., Bu, Z., Pulendran, B., Compans, R. W., & Yang, C. (2006) · Virology · doi:10.1016/j.virol.2006.03.021 · Cited by 104
Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection
Warfield, K. L., Swenson, D. L., Negley, D. L., Schmaljohn, A. L., Aman, M. J., & Bavari, S. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.01.063 · Cited by 99
Self-citationProtective efficacy of neutralizing antibodies against Ebola virus infection
Takada, A., Ebihara, H., Jones, S. J. M., Feldmann, H., & Kawaoka, Y. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.09.076 · Cited by 91
Olinger, G. G., Bailey, M. A., Dye, J. M., Bakken, R. R., Kuehne, A. I., Kondig, J., Wilson, J., Hogan, R. J., & Hart, M. K. (2005) · Journal of Virology · doi:10.1128/jvi.79.22.14189-14196.2005 · Cited by 88
Self-citationFilovirus‐Like Particles Produced in Insect Cells: Immunogenicity and Protection in Rodents
Warfield, K. L., Posten, N. A., Swenson, D. L., Olinger, G. G., Esposito, D., Gillette, W., Hopkins, R. F., Costantino, J. A., Panchal, R. G., Hartley, J. L., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/520612 · Cited by 85
Self-citationHuman papilloma virus (HPV) and cervical cancer.
Furumoto, H., & Irahara, M. (2002) · PubMed · Cited by 73
Filovirus-like particles as vaccines and discovery tools
Warfield, K. L., Swenson, D. L., Demmin, G. L., et al. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.3.429 · Cited by 49
Self-citationStanley, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802174-3.00013-8 · Cited by 33
Cited by
Feldmann, H., & Geisbert, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)60667-8 · Cited by 1,374
Kushnir, N., Streatfield, S. J., & Yusibov, V. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.083 · Cited by 587
Design of virus-based nanomaterials for medicine, biotechnology, and energy
Wen, A. M., & Steinmetz, N. F. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00287g · Cited by 379
Geisbert, T. W., Geisbert, J. B., Leung, A., Daddario-DiCaprio, K. M., Hensley, L. E., Grolla, A., & Feldmann, H. (2009) · Journal of Virology · doi:10.1128/jvi.00561-09 · Cited by 275
A comprehensive atlas of immunological differences between humans, mice, and non-human primates
Bjornson-Hooper, Z. B., Fragiadakis, G. K., Spitzer, M. H., Chen, H., Madhireddy, D., Hu, K., Lundsten, K., McIlwain, D. R., & Nolan, G. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867015 · Cited by 215
Metadata
- Authors
- Warfield, K. L., Swenson, D. L., Olinger, G. G., Kalina, W. V., Aman, M. J., & Bavari, S.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-11-15
- Volume
- 196
- Issue
- s2
- Pages
- S430-S437
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W1982830459
- Cited by
- 260
- References
- 33
- FWCI
- 8.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.